Intersect ENT (XENT) Reports Slight Revenue Miss; Piper Jaffray Cuts Price Target to $23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Intersect ENT Reports Third Quarter 2015 Results
November 4, 2015 4:05 PM ESTRevenue Increased 56% Year over Year and Gross Margin at 80%
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2015.
Recent Highlights
Achieved third quarter revenue of $14.2 million, an increase of 56% over the third quarter 2014. Realized third quarter gross margin of 80% compared to 72% in the third quarter 2014.... More